Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Grace Stutzmann
Rosalind Franklin Univ of Medicine & Sci, Department: Neurosciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Neurolucent, Inc
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Stutzmann owns a portion of Neurolucent, Inc., a for-profit start-up company that has acquired a license to a patent from RFUMS that is related to the research involved in this project. RFUMS made the determination that this interest could be affected by the research results.
Validating novel ryanodine receptor-targeted compounds for AD therapeutics
The objective of this study is to test and optimize a series of small molecule compounds for the treatment and prevention of Alzheimer's disease using clinically-relevant AD mouse models, ryanodine receptor (RyR) expressing model cells, and neurons generated from human AD patients and age-matched controls. These compounds are designed to allosterically regulate RyR function and stabilize dysregulated calcium signaling in human neurons from AD patients and in AD mouse models. The rationale is based on findings that disruptions in RyR-mediated calcium signaling are a central component of AD pathogenesis, and, treatment with compounds that stabilize calcium signaling provide broad-spectrum therapeutic effects in AD mouse models.
Filed on April 22, 2016.
Tell us what you know about Grace Stutzmann's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Grace Stutzmann filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Grace E. Stutzmann | Rosalind Franklin Univ of Medicine & Sci | Conflict of Interest | Neurolucent | Value cannot be readily determined |
| Grace E. Stutzmann | Rosalind Franklin Univ of Medicine & Sci | Conflict of Interest | Neurolucent, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.